← All trials
NCT05251493
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 6, 2022
- Primary completion
- May 31, 2023
- Completion date
- May 31, 2023
- First posted
- Feb 22, 2022
- Last posted
- Jun 10, 2022
- Enrollment
- 280
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of CanadaLead sponsor
- Government of CanadaOverall official - principal investigator
- Government of CanadaReponsible party - principal investigator
- Saskatchewan Centre for Patient-Oriented ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.